NLRP3 and asthma: Primiano et al. showed that oral administration of MCC950 prior to sensitization in an acute HDM-induced asthma model, not only efficiently inhibited NLRP3 and reduced IL1β levels, but importantly, also blocked asthma development and reduced the levels of Th2 cytokines and eosinophil and neutrophil recruitment (154).